Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2021 | The role of ASCT in amyloidosis

Pieter Sonneveld • 6 Oct 2021
COSTEM 2021
Amyloidosis Multiple Myeloma Rare Diseases

Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, comments on the role of autologous stem cell transplantation (ASCT) in the treatment of patients with amyloidosis. Prof. Sonneveld describes how poor tolerability to intensive therapies is a major challenge to ASCT for these patients. Nevertheless, several studies have reported positive results for ASCT. In addition, Prof. Sonneveld describes how novel agents initially developed to treat myeloma have also demonstrated efficacy in amyloidosis. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Pieter Sonneveld

2:54
The PERSEUS trial: primary results of D-VRd vs VRd in newly diagnosed, transplant eligible MM
Pieter Sonneveld • 11 Dec 2023
Reaching a cure for multiple myeloma
Gareth Morgan et al. • 15 Apr 2023
1:57
The benefit of double autologous transplantation in multiple myeloma patient subgroups
Pieter Sonneveld • 24 Oct 2022
1:27
Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma?
Pieter Sonneveld • 24 Oct 2022

Related Videos

2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:07
Key advancements in the treatment of BPDCN from EBMT 2024
Cristina Papayannidis • 22 Apr 2024
1:27
First-line tagraxofusp followed by alloSCT in BPDCN: a case study
Cristina Papayannidis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals